The information was submitted to the public on January 22, 2016 at 8:20 CET
CellaVision will publish the year-end bulletin for 2015 on February 12, 2016 at 08:20 CET. The report will be available at www.cellavision.com
In connection with the release of the interim report analysts, investors and media are hereby invited to a telephone conference and audio webcast at 10:00 CET where Zlatko Rihter, CEO, will present and comment the report.
The presentation will be in English via a conference call or audio webcast: http://cloud.magneetto.com/wonderland/2016_0212_Cellavision/view
Phone number for the conference:
SE: +46 8 566 426 92
UK: +44 203 428 14 06
US: +1855 753 22 36
No pre-registration is required. Please dial in 5-10 minutes prior to the scheduled start time in order to facilitate a timely start.
CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products rationalize manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the mother company in Lund and by the market support organizations in the USA, Canada, China and Japan. In 2014 sales were SEK 217 million and sales continue to increase, with a growth target of at least 15 % per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq OMX Stockholm, Small Cap list. Read more at www.cellavision.com
This announcement is distributed by NASDAQ OMX Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: CellaVision AB, Ideon Science Park, Lund 223 70, Sweden
If you would like to unsubscribe and stop receiving these e-mails click here.